##
##
|~
w
~ ~
~|
|---|
|Description ofthe charity's trusts|
|Type ofgoverning
document
Constitution
(adopted 21"October 1983,amended
24'" September 1984,
15'"September 2009, 9~September 2013, 22"' September 2014, 21"
Se tember 2015, 22"4 Se tember 2016, 25rc Se tember 2018|
|How the charity is constituted
Association|
|Trustee selection methods
Trustees are elected to membership
ofthe Executive Committee
by BIHS
Members at the Annual
Business Meeting
following
a call for nominations|
|earlier
in the year|
|Additional
governance
issues (Optional
information)|
|You may choose to include
additional
information,
where
relevant,
about:
Ordinary
and Associate Membership
and Fellowship ofthe BIHS is open to all
registered
healthcare
professionals
active in the field of hypertension
and
cardiovascular
disease prevention
in the United
Kingdom
and the Republic of
Ireland.
Affiliate
membership
may be granted to healthcare
professionals|
|~
policies and procedures
residing
outside the United
Kingdom
and Republic of Ireland at the discretion|
|adopted
for the induction
ofthe Executive Committee.
It includes
clinicians,
nurses,
physiologists
and|
|and training oftrustees;
other scientists.
Applications
for membership
are considered
throughout
the|
|~
the charity's
organisationai
year.
Membership
ofthe Society currently
stands at 298. Only members
and|
|structure
and any wider
fellows resident
in the United
Kingdom
and Republic of Ireland are eligible for|
|network
with which the
election to the Executive Committee.|
|charity works;|
|~
relationship
with any related
parties;
The management
ofthe BIHS is undertaken
by an elected Executive
Committee
of9 persons (Trustees),
led by the President
and Vice President.|
|~
trustees'
consideration
of
major risks and the system
and procedures
to manage
them.
Seven Working
Parties have also been established
to help the Executive
Committee
manage the day-to-day
activities ofthe Society (at least one
Trustee sits on each ofthe Working
Parties, which are required to submit
regular
reports to the Executive Committee
on its activities).|
|The major risks to the continuation
ofthe Society's programme
ofeducational|
|activities are from a decrease
in income from its industrial
partners (see under|
|'Reserves
Policy'). Minimal fees to cover administration
costs only have been|
|introduced
for vadous projects.|
|~ ~|
|Summary
ofthe
The object ofthe Charity
is to promote the advancement
of knowledge
and|
|oblecta ofthe charity
dissemination
of information
concerning
the pathophysiology,
epidemiology,
detection,|
|act out in ita
governing
document
investigation
and treatment
of arterial
hypertension
and related cardiovascular
diseases|
|Summary
ofthe
main activities
undertaken
for
the public benefit
in relation to
these objects
(include within
this section the
statutory
declaration
that
trustees
have had
~
Educational
Meetings:
Each year, the Society aims to run a main Scientific
Meeting. Educational
programmes
are under review and online options are being
explored. Various other meetings
are held during
the year;
in collaboration
with
other cognate societies and/or as ad hoc meetings
on specific topics
~
Guidelines
and Scientific Statements:
The Society is a stakeholder
in various
National
Institute
for Clinical Excellence Guidelines
relating to cardiovascular
disease and issues statements
in response to relevant
media reports
Website:
The aids website
(~www. bihsoc. or ) provides
a valuable
educational
resource for healthcare
professionals
working
in the field of high blood pressure.
These resources have been increased
and enhanced
over the last few years and|
|TAR
April 2009|
##
##
##
##
##
##
##
##
##
##
||||Page|
|---|---|---|---|
|Independent|examiner's
report|||
|Statement
oF|financial|activities||
|Balance sheet||||
|Notes to the financial||statements|4-9|
##
##
##
##
##
##
||||Unrestricted|Unrestricted|
|---|---|---|---|---|
||||funds|funds|
||||2021|2020|
|||Notes|||
|Incornl f49/n:|||||
|Donations
and legacies
*' liu|||2,000|112|
|Conferences
and meetings|||197,394|1,259|
|Membership
subscriptions|||14.109|13.684|
|Somal programmes|||||
||||3,617||
|OMRON hcensing
agreement|||17,000|17,000|
|Exhibition
and sponsorship|||13,000||
|Derivative
device applications|||11,000|2,000|
|Investments|||16,161|17,074|
|Total income|||274,281|51,129|
|d|||||
|Charitable
aclivities|||159,431|100,975|
|Net gains/(losses)
on investments||9|70,794|32,181|
|Net income/(expenditure)|for the year/||||
|Net incoming/(outgoing)|resources||185,644|(17,665)|
|Other recognised
gains and losses|||||
|Other gains or losses||10||1,869|
|Net movement
in funds|||185,644|(15,796)|
|Fund balances at 1 January|2021||603,336|619,132|
|Fund balances at 31 December 2021|||788,980|603,336|
##
##
##
||||||2021||2020||
|---|---|---|---|---|---|---|---|---|
||||Notes||f||f||
|Fixed assets|||||||||
|Tangible assets|||||||||
|Current assets|||||||||
|Debtors|||11|16,148|||13,554||
|Investments|||12|723,330|||533,963||
|Cash at bank and|in|hand||81,088|||74,477||
|||||820,566|||621,994||
|Creditors: amounts
one year||falling due within|13|(31,586)|||(18,658)||
|Net current assets||||||788,980||603,336|
|Income funds|||||||||
|Unrestricted
funds||||||788,980||603,336|
|||||||788,980||603,336|
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
||||||Unrestricted|Unrestricted|
|---|---|---|---|---|---|---|
||||||funds|funds|
||||||2021|2020|
||||||f:|E|
||Donations|and|gifts||2,000|112|
|4|Investments||||||
||||||Unrestricted|Unreslricied|
||||||funds|funds|
||||||2021
F|2020f|
||Dividends|and|interest|receivable|16,161|'17,074|
##
##
|6|Support costs|||||||
|---|---|---|---|---|---|---|---|
|||Support|Governance|2021|Support costs|Governance|2020|
|||costs|costs|||costs||
|||f|6|6|6|f||
||Depreciation||||232||232|
||Exchange Losses|6,347||6,347||||
||Admin costs
Finance costs|46,942
962||46,942
962|45,606
588||45,606
588|
|||54,251||54,251|46,426||46,426|
||Analysed
between|||||||
||Charitable
acbvities|54,251||54,251|46,426||46,426|
##
|||||||2021|2020|
|---|---|---|---|---|---|---|---|
|||||||Number|Number|
||Tota|I||||||
|9|Net|gains/(losses)||on investments||||
|||||||2021|2020|
||Unreatised||gain/(loss)||on COIF account|70,794|32,181|
|10|Other gains or losses|||||||
|||||||2021|2020|
||Foreign exchange|||gains|||1,869|
##
##
##
|11|Debtors||||||
|---|---|---|---|---|---|---|
||||||2021|2020|
||Amounts
falling due|||within one year:|8|f|
||Trade debtors||||3,258|38|
||Other debtors||||11,828|5,615|
||Prepayments|and accrued income|||1,062|7,901|
||||||16,148|13,554|
|12|Current asset||investments||||
||||||2021|2020|
||||||8|6|
||Unlisted
investments||||723,330|533,963|
|13|Creditors: amounts|||falling due within one year|2021|2020|
|||||||6|
||Other taxation
Trade creditors||and social security||29,586|2,583
2,308|
||Other creditors|||||195|
||Accruals and|deferred||income|2,000|13,572|
||||||31,586|18,658|
##
##
##
##
##
##
||||Page|
|---|---|---|---|
|Independent|examiner's
report|||
|Statement
oF|financial|activities||
|Balance sheet||||
|Notes to the financial||statements|4-9|
##
##
##
##
##
##
||||Unrestricted|Unrestricted|
|---|---|---|---|---|
||||funds|funds|
||||2021|2020|
|||Notes|||
|Incornl f49/n:|||||
|Donations
and legacies
*' liu|||2,000|112|
|Conferences
and meetings|||197,394|1,259|
|Membership
subscriptions|||14.109|13.684|
|Somal programmes|||||
||||3,617||
|OMRON hcensing
agreement|||17,000|17,000|
|Exhibition
and sponsorship|||13,000||
|Derivative
device applications|||11,000|2,000|
|Investments|||16,161|17,074|
|Total income|||274,281|51,129|
|d|||||
|Charitable
aclivities|||159,431|100,975|
|Net gains/(losses)
on investments||9|70,794|32,181|
|Net income/(expenditure)|for the year/||||
|Net incoming/(outgoing)|resources||185,644|(17,665)|
|Other recognised
gains and losses|||||
|Other gains or losses||10||1,869|
|Net movement
in funds|||185,644|(15,796)|
|Fund balances at 1 January|2021||603,336|619,132|
|Fund balances at 31 December 2021|||788,980|603,336|
##
##
##
||||||2021||2020||
|---|---|---|---|---|---|---|---|---|
||||Notes||f||f||
|Fixed assets|||||||||
|Tangible assets|||||||||
|Current assets|||||||||
|Debtors|||11|16,148|||13,554||
|Investments|||12|723,330|||533,963||
|Cash at bank and|in|hand||81,088|||74,477||
|||||820,566|||621,994||
|Creditors: amounts
one year||falling due within|13|(31,586)|||(18,658)||
|Net current assets||||||788,980||603,336|
|Income funds|||||||||
|Unrestricted
funds||||||788,980||603,336|
|||||||788,980||603,336|
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
||||||Unrestricted|Unrestricted|
|---|---|---|---|---|---|---|
||||||funds|funds|
||||||2021|2020|
||||||f:|E|
||Donations|and|gifts||2,000|112|
|4|Investments||||||
||||||Unrestricted|Unreslricied|
||||||funds|funds|
||||||2021
F|2020f|
||Dividends|and|interest|receivable|16,161|'17,074|
##
##
|6|Support costs|||||||
|---|---|---|---|---|---|---|---|
|||Support|Governance|2021|Support costs|Governance|2020|
|||costs|costs|||costs||
|||f|6|6|6|f||
||Depreciation||||232||232|
||Exchange Losses|6,347||6,347||||
||Admin costs
Finance costs|46,942
962||46,942
962|45,606
588||45,606
588|
|||54,251||54,251|46,426||46,426|
||Analysed
between|||||||
||Charitable
acbvities|54,251||54,251|46,426||46,426|
##
|||||||2021|2020|
|---|---|---|---|---|---|---|---|
|||||||Number|Number|
||Tota|I||||||
|9|Net|gains/(losses)||on investments||||
|||||||2021|2020|
||Unreatised||gain/(loss)||on COIF account|70,794|32,181|
|10|Other gains or losses|||||||
|||||||2021|2020|
||Foreign exchange|||gains|||1,869|
##
##
##
|11|Debtors||||||
|---|---|---|---|---|---|---|
||||||2021|2020|
||Amounts
falling due|||within one year:|8|f|
||Trade debtors||||3,258|38|
||Other debtors||||11,828|5,615|
||Prepayments|and accrued income|||1,062|7,901|
||||||16,148|13,554|
|12|Current asset||investments||||
||||||2021|2020|
||||||8|6|
||Unlisted
investments||||723,330|533,963|
|13|Creditors: amounts|||falling due within one year|2021|2020|
|||||||6|
||Other taxation
Trade creditors||and social security||29,586|2,583
2,308|
||Other creditors|||||195|
||Accruals and|deferred||income|2,000|13,572|
||||||31,586|18,658|
##